> Details

Topp, Max S.; Gökbuget, Nicola; Zugmaier, Gerhard; Degenhard, Evelyn; Goebeler, Marie-Elisabeth; Klinger, Matthias; Neumann, Svenja A.; Horst, Heinz A.; Raff, Thorsten; Viardot, Andreas; Stelljes, Matthias; Schaich, Markus; Köhne-Volland, Rudolf; Brüggemann, Monika; Ottmann, Oliver G.; Burmeister, Thomas; Baeuerle, Patrick A.; Nagorsen, Dirk; Schmidt, Margit; Einsele, Hermann; Riethmüller, Gert; Kneba, Michael; Hoelzer, Dieter; Kufer, Peter;

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
  • Contributor: Topp, Max S.; Gökbuget, Nicola; Zugmaier, Gerhard; Degenhard, Evelyn; Goebeler, Marie-Elisabeth; Klinger, Matthias; Neumann, Svenja A.; Horst, Heinz A.; Raff, Thorsten; Viardot, Andreas; Stelljes, Matthias; Schaich, Markus; Köhne-Volland, Rudolf; Brüggemann, Monika; Ottmann, Oliver G.; Burmeister, Thomas; Baeuerle, Patrick A.; Nagorsen, Dirk; Schmidt, Margit; Einsele, Hermann; Riethmüller, Gert; Kneba, Michael; Hoelzer, Dieter; Kufer, Peter;
  • Published: American Society of Hematology, 2012
  • Published in: Blood, 120 (2012) 26, Seite 5185-5187
  • Language: English
  • DOI: 10.1182/blood-2012-07-441030
  • ISSN: 0006-4971; 1528-0020
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title> <jats:p>Persistence or recurrence of minimal residual disease (MRD) after chemotherapy results in clinical relapse in patients with acute lymphoblastic leukemia (ALL). In a phase 2 trial of B-lineage ALL patients with persistent or relapsed MRD, a T cell–engaging bispecific Ab construct induced an 80% MRD response rate. In the present study, we show that after a median follow-up of 33 months, the hematologic relapse-free survival of the entire evaluable study cohort of 20 patients was 61% (Kaplan-Meier estimate). The hema-tologic relapse-free survival rate of a subgroup of 9 patients who received allogeneic hematopoietic stem cell transplantation after blinatumomab treatment was 65% (Kaplan-Meier estimate). Of the subgroup of 6 Philadelphia chromosome–negative MRD responders with no further therapy after blinatumomab, 4 are in ongoing hematologic and molecular remission. We conclude that blinatumomab can induce long-lasting complete remission in B-lineage ALL patients with persistent or recurrent MRD. The original study and this follow-up study are registered at www.clinicaltrials.gov as NCT00198991 and NCT00198978, respectively.</jats:p>
  • Access State: Open Access